Idenix Pharmaceuticals (NASDAQ:[[ticker:IDIX]]), a Cambridge, MA-based developer of anti-viral drugs, announced today in a press release that it has priced a secondary public offering of 7.25 million shares at $3.14 each. Idenix expects to raise $21.2 million from the offer, which is expected to close on August 10, after processing fees and other costs. The company is currently developing treatments for Hepatitis C.